Maha Katabi - 30 Jan 2024 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Director
Signature
/s/ Nathalie Auber, as attorney-in-fact
Issuer symbol
VERA
Transactions as of
30 Jan 2024
Net transactions value
+$4,999,990
Form type
4
Filing time
01 Feb 2024, 17:58:54 UTC
Previous filing
04 Jan 2024
Next filing
27 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Purchase $4,999,990 +161,290 +4.7% $31.00 3,628,446 30 Jan 2024 By Sofinnova Venture Partners X, L.P. F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.P. ("SM X LP") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. ("SM X LLC") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.